Clinical Trials Sponsored by Otsuka Pharmaceutical Development and Commercialization, Inc.

Total 270 results

Otsuka Pharmaceutical Development & Commercialization...

Terminated

To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

Tuberculosis, Pulmonary | Extensively Drug-Resistant Tuberculosis | Tuberculosis, Multidrug Resistant

Korea, Republic of, China, United States, Egypt, Estonia, Japan, Latvia, Peru, Philippines
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis

Tuberculosis

Latvia, Lithuania
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683

Tuberculosis, Multidrug-Resistant

Korea, Republic of, China, Estonia, Latvia, Peru, Philippines
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

United States, Australia, Bulgaria, Romania, India, Slovakia, Philippines
Otsuka Pharmaceutical Development & Commercialization...

Completed

Tolvaptan Extension Study in Participants With ADPKD (TEMPO 4/4)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States, Australia, Belgium, Germany, Italy, Poland, Romania, United Kingdom, Argentina, Canada, France, Netherlands, Russian Federation
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)

Multidrug Resistant Tuberculosis

Philippines, South Africa
Otsuka Pharmaceutical Development & Commercialization...

Completed

Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant

Belgium, Germany, Italy, Spain, Sweden, United States, Canada, Australia, Netherlands, Czechia, Poland, Denmark, Israel, Hungary, Russian Federation, South Africa, United Kingdom, Romania, Argentina, Norway
Otsuka Pharmaceutical Development & Commercialization...

Terminated

A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

Schizophrenia | Major Depressive Disorder | Bipolar 1 Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (NOCTURNE)

Autosomal Dominant Polycystic Kidney Disease

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole

Nervous System Diseases | Schizophrenia | Mental Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

Chronic Kidney Disease | Autosomal Dominant Polycystic Kidney Disease

Australia, Belgium, Italy, Spain, Sweden, United States, Canada, Netherlands, Czechia, Poland, Germany, Russian Federation, Hungary, Israel, Puerto Rico, Argentina, Denmark, South Africa, United Kingdom, Norway, France, Romania
Otsuka Pharmaceutical Development & Commercialization...

Completed

Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1) (OSMITTER)

Device Latency

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Poland, Serbia, Russian Federation, Germany, Canada, France
Otsuka Pharmaceutical Development & Commercialization...

Completed

Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis

Pediatric | Multidrug Resistant Tuberculosis

Philippines, South Africa
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features. (ATTAIN 267)

Adolescent Schizophrenia | Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features

India, United States, Bulgaria, Croatia, Hungary, Malaysia, Philippines, Poland, Romania, Russian Federation, Serbia, Taiwan, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia (STEP 203)

Schizophrenia

United States, Croatia, Serbia, Bulgaria, India, Korea, Republic of, Philippines, Romania, Russian Federation, Slovakia, Taiwan, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization...

Withdrawn

Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

Nervous System Diseases | Schizophrenia | Mental Disorder | Bipolar 1 Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia (ATTAIN 266)

Schizophrenia

United States, India, Malaysia, Philippines, Romania, Russian Federation, Taiwan
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia (SALACIA)

Hyponatremia | Inappropriate ADH Syndrome | Dilutional Hyponatremia

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer

Advanced Cancer

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder

Bipolar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Aripiprazole in Children and Adolescents With Bipolar I Disorder

Bipolar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

Ulcerative Colitis

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

Congestive Heart Failure

United States, Canada, Netherlands, United Kingdom, France, Spain, Germany, Switzerland, Italy, Brazil, Argentina, Russian Federation, Belgium, Romania, Czech Republic, Norway, Poland, Sweden
Otsuka Pharmaceutical Development & Commercialization...

Completed

Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents

Schizophrenia | Mania
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

Pain | Advanced Cancer

United States, United Kingdom, Bulgaria, Belgium, Poland, Hungary, Romania, Czechia, Puerto Rico, Lithuania, Germany, Latvia
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode

Bipolar Disorder

United States, Puerto Rico
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

Bipolar I Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole in Patients With Acute Mania

Bipolar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Schizophrenia Trial of Aripiprazole

Schizophrenia

Austria, United Kingdom, France, Spain, Sweden, Czech Republic, Denmark, Finland, Germany
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in Patients With Bipolar I Disorder

Bipolar Disorder

France, Portugal, Spain, Italy, Germany, South Africa, United Kingdom, United States, Russian Federation, Poland, Czech Republic, Hungary, Netherlands, Estonia, Australia, Bulgaria, Switzerland
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Withdrawn

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

Bipolar Disorder

United States, India
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania

Bipolar Disorder

United States, South Africa, Brazil, Russian Federation, France, Czechia, Croatia, India, Bulgaria
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Autistic Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

Behavioral Symptoms | Autistic Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Behavioral Symptoms | Autistic Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

Bipolar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

Dementia | Alzheimer's Disease

United States

Clinical Trials Sponsored by Otsuka Pharmaceutical Development and Commercialization, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations